The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future
A Tseng, J Seet, EJ Phillips - British journal of clinical …, 2015 - Wiley Online Library
The evolution of human immunodeficiency virus (HIV) treatment has improved our
understanding and management of complex pharmacological issues that have driven …
understanding and management of complex pharmacological issues that have driven …
Single-tablet regimens in HIV therapy
N Astuti, F Maggiolo - Infectious diseases and therapy, 2014 - Springer
Combined antiretroviral therapy (cART) has evolved considerably over the past decades
leading to a better control of human immunodeficiency virus replication. Recently, regimens …
leading to a better control of human immunodeficiency virus replication. Recently, regimens …
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine …
A Pozniak, M Markowitz, A Mills… - The Lancet Infectious …, 2014 - thelancet.com
Background Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil
fumarate (tenofovir) might be a safe and efficacious switch option for virologically …
fumarate (tenofovir) might be a safe and efficacious switch option for virologically …
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
D Churchill, L Waters, N Ahmed, B Angus… - HIV …, 2016 - discovery.ucl.ac.uk
The overall purpose of these guidelines is to provide guidance on best clinical practice in
the treatment and management of adults with HIV infection on antiretroviral therapy (ART) …
the treatment and management of adults with HIV infection on antiretroviral therapy (ART) …
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated …
A Pozniak, J Flamm, A Antinori, M Bloch, D Ward… - HIV Clinical …, 2017 - Taylor & Francis
Background: HIV-1-infected, virologically suppressed adults wanting to simplify or change
their non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens may benefit …
their non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens may benefit …
Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia …
P de expertos de GeSIDA, PN sobre el Sida - Enfermedades Infecciosas y …, 2014 - Elsevier
Objetivo Actualizar las recomendaciones sobre el tratamiento antirretroviral (TAR) para
adultos infectados por el VIH-1. Métodos Este documento ha sido consensuado por un …
adultos infectados por el VIH-1. Métodos Este documento ha sido consensuado por un …
Switching strategies in the recent era of antiretroviral therapy
P Prieto, D Podzamczer - Expert review of clinical pharmacology, 2019 - Taylor & Francis
Introduction Although antiretroviral therapy is highly effective, many patients may benefit
from switching strategies. Rapid advances in the development of new antiretroviral drugs …
from switching strategies. Rapid advances in the development of new antiretroviral drugs …
An investigation of liquid chromatography–mass spectral attributes and analytical performance characteristics of tenofovir, emtricitabine and efavirenz in human …
SM Ndolo, K Sichilongo, A Massele… - Journal of analytical …, 2016 - academic.oup.com
Liquid chromatography (LC) and mass spectral behavior and analytical performance
characteristics of efavirenz (EFV), emtricitabine (EMT) and tenofovir (TFV), ie, individual …
characteristics of efavirenz (EFV), emtricitabine (EMT) and tenofovir (TFV), ie, individual …
Switching to coformulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
C Pinnetti, S Di Giambenedetto… - JAIDS Journal of …, 2015 - journals.lww.com
Because of the availability of rilpivirine coformulated with tenofovir/emtricitabine
(RPV/FTC/TDF) in a single-tablet regimen (STR) and to a favorable tolerability profile, 4, 5 …
(RPV/FTC/TDF) in a single-tablet regimen (STR) and to a favorable tolerability profile, 4, 5 …
Switching antiretroviral regimes for the treatment of HIV: safety implications
L Utrillo, F Vidal, T Puig, P Domingo - Expert Opinion on Drug …, 2016 - Taylor & Francis
Introduction: There are multiple reasons to switch from a virologically successful
antiretroviral regimen. Some of them are related to toxicity. Lately, combination antiretroviral …
antiretroviral regimen. Some of them are related to toxicity. Lately, combination antiretroviral …